INmune Bio Inc. (INMB) News
Follow INmune Bio Inc. (INMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Inmune Bio adds R. Duane Clark II and James Sapirstein to board
Inmune Bio appointed R. Duane Clark II and James Sapirstein to its Board of Directors and named both to the Nominating and Corporate Governance Committee.Original SEC Filing: Inmune Bio, Inc. [ INMB ] - 8-K - Sep. 14, 20
REGULATION | Sep 14, 2026, 08:13 PM UTC
L
INmune Bio to present at H.C. Wainwright Global Investment Conference
INmune Bio said its on-demand presentation will be available September 11, 2026, at 7:00 A.M. (ET).
EQUITY | Sep 09, 2026, 12:03 PM UTC
L
INMB - INmune Bio to Present at the H.C. Wainwright Global Investment Conference
INMB - INmune Bio to Present at the H.C. Wainwright Global Investment Conference
EQUITY | Sep 09, 2026, 12:01 PM UTC
L
INmune Bio advances Ebstrocel toward EMA marketing authorization
INmune Bio says it has advanced Ebstrocel toward European marketing authorization via EMA regulatory filings, per TradeXchange Newsdesk.
EQUITY | Aug 26, 2026, 11:00 AM UTC
M
INmune Bio Receives $4.6M R&D Rebates
INmune Bio gets $4.6M R&D rebates
EQUITY | Jul 31, 2026, 11:00 AM UTC
L
INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th - Click For Rele
INMB - INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
EARNINGS | Jul 31, 2026, 11:00 AM UTC
M
INMB Establishes Scientific Advisory Board
INMB forms advisory board for CORDStrom platform
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study
INMB Inmune bio’s xpro1595 prevents brain-injury-induced Alzheimer's pathology, memory loss, and pain in new peer-reviewed preclinical study Inmune Bio - xpro1595 selectively neutralizes soluble tnf - Cordstrom to file m
EQUITY | Jul 15, 2026, 11:02 AM UTC
L
INmune Bio Submits Its CORDStrom Platform Patent Application Into The U.S. National Phase Before USPTO
Submission advances a key element of the Company’s global intellectual property strategy for its next-generation mesenchymal stromal cell (MSC) platform. Highlights Advanced to U.S. National Phase: The Company has offici
EQUITY | Jul 01, 2026, 11:07 AM UTC
H
INMB: UK Approves PIP
The UK Medicines & Healthcare Products Regulatory Agency approves the Pediatric Investigation Plan for INmune Bio's Ebstrocel for Recessive Dystrophic Epidermolysis Bullosa
EQUITY | Jun 25, 2026, 11:13 AM UTC
M
INMB Gets MHRA Approval
INmune Bio Inc. achieves MHRA approval of PIP for CORDStrom
EQUITY | Jun 25, 2026, 11:00 AM UTC
M
INMB Receives MHRA Alignment
INmune Bio receives MHRA written alignment supporting planned 2026 UK conditional marketing authorization application for CORDStrom in RDEB
EQUITY | Jun 23, 2026, 12:02 PM UTC